Abstract:Although FTY720 may alter migration and homing of lymphocytes via sphingosine-1-phosphate (S1P) receptors, our recent studies indicated that FTY720 directly controls the differentiation of Th1 cells to regulatory T cells (Tregs) by targeting S1P1. However, the pharmacological function of FTY720 in immunological hepatic injury remains unknown. In this study, the role and regulatory signaling pathway of S1P receptor were investigated using a pharmacological approach in immune-mediated hepatic injury (IMH). In the context of IMH, FTY720 significantly ameliorated mortality and hepatic pathology. In FTY720-treated mice, recruited CD11b + Gr1 + myeloid-derived suppressor cells (MDSCs) mediate protection against IMH and are functional suppressive immune modulators that result in fewer IFN-g–producing Th1 cells and more Foxp3 + Tregs. In agreement, FTY720-treated MDSCs promote the reciprocal differentiation between Th1 cells and Tregs in vitro and in vivo. Mechanistically, FTY720 treatment induced inducible NO synthase expression and NO production in MDSCs. Pharmacologic inhibition of inducible NO synthase completely eliminates MDSC suppressive function and eradicates their inducible effects on T cell differentiation. Finally, the mTOR inhibitor, rapamycin, photocopies the effects of FTY720 on MDSCs, implicating mTOR as a downstream effector of S1P1 signaling. This study identifies MDSCs as an essential component that provides protection against IMH following FTY720 or rapamycin treatment, validating the S1P1–mTOR signaling axis as a potential therapeutic target in hepatic injury. L iver diseases are associated with significant mortality and represent a major global health problem. Immune-mediated hepatic injury is involved in liver disease that is triggered by a variety of agents, including autoimmune hepatitis and viral hepatitis (1, 2). T cell–mediated immune responses play a critical role in a variety of liver injuries. Activated CD4 + T cells represent the predominant population of T cells that infiltrate the liver in human autoimmune liver diseases (3–5). The injection of Con A in rodents rapidly induces polyclonal T cell activation, which leads to clinical and histological symptoms of acute hepatitis (6, 7). The liver injury of T cell–mediated immunity in human acute hepatitis mimicked in mice by a delayed-type hypersensitivity to picryl chloride (PIH) (8–12). This hepatic injury is mediated by CD4 + T cells. An imbalance of Th1 cells, regulatory T cells (Tregs), and Th2 cells induces acute liver injury. As well-established experimental mouse models of autoimmune liver disease , Con A–induced hepatitis (CIH) and PIH have been used extensively to study the pathophysiology of immune-mediated hepatic injury. Myeloid-derived suppressor cells (MDSCs) are …

Mtor Limits the Recruitment of CD11b+Gr1+Ly6Chigh Myeloid-Derived Suppressor Cells in Protecting Against Murine Immunological Hepatic Injury.

Mtor Signaling Disruption from Myeloid-Derived Suppressive Cells Protects Against Immune-Mediated Hepatic Injury Through the HIF1α-dependent Glycolytic Pathway.

The Mtor Signal Regulates Myeloid Derived Suppressor Cells Differentiation and Immunosuppressive Function in Acute Kidney Injury

mTOR masters monocytic myeloid-derived suppressor cells in mice with allografts or tumors

Mtor Signaling Regulates the Development and Therapeutic Efficacy of PMN-MDSCs in Acute GVHD.

The Selective Mtorc1, Rather Than Dual Mtorc1/2, Inhibition Confers Liver Protection from Ischemia and Reperfusion Injury.

The Mtor Deficiency in Monocytic Myeloid-Derived Suppressor Cells Protects Mouse Cardiac Allografts by Inducing Allograft Tolerance

Mtor Inhibitor Rapamycin Induce Polymorphonuclear Myeloid-Derived Suppressor Cells Mobilization and Function in Protecting Against Acute Graft-Versus-host Disease after Bone Marrow Transplantation

Targeting S1P1 Receptor Protects Against Murine Immunological Hepatic Injury Through Myeloid-Derived Suppressor Cells.

Mtor Activation Protects Liver from Ischemia/reperfusion‐induced Injury Through NF‐κB Pathway

Regulatory effect of rapamycin on recruitment and function of myeloid-derived suppressor cells in heart failure

IDDF2019-ABS-0174 Targeting Monocyte-Intrinsic Enhancer Reprogramming Improves Immunotherapy Efficacy in Hepatocellular Carcinoma

Repression of Mammalian Target of Rapamycin Complex 1 Inhibits Intestinal Regeneration in Acute Inflammatory Bowel Disease Models.

Mtor-Mediated Glycolysis Contributes to the Enhanced Suppressive Function of Murine Tumor-Infiltrating Monocytic Myeloid-Derived Suppressor Cells

Mtor Inhibition Improves the Immunomodulatory Properties of Human Bone Marrow Mesenchymal Stem Cells by Inducing COX-2 and PGE(2)

Interferon-γ-Induced Myeloid-Derived Suppressor Cells Aggravate Kidney Ischemia-Reperfusion Injury by Regulating Innate Immune Cells.

Transient Mtor Inhibition Facilitates Continuous Growth Of Liver Tumors By Modulating The Maintenance Of Cd133+Cell Populations

Transient Inhibition of Mtorc1 Signaling Ameliorates Irradiation-Induced Liver Damage

Mammalian target of rapamycin activation underlies HSC defects in autoimmune disease and inflammation in mice.

Tumor Microenvironment Modulates Immunological Outcomes of Myeloid Cells with mTORC1 Disruption

Targeting the MDSCs of Tumors In Situ With Inhibitors of the MAPK Signaling Pathway to Promote Tumor Regression